Guggenheim Capital LLC Sells 82,768 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Guggenheim Capital LLC reduced its holdings in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 53.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 73,081 shares of the biopharmaceutical company's stock after selling 82,768 shares during the quarter. Guggenheim Capital LLC's holdings in Royalty Pharma were worth $1,864,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in RPRX. Swedbank AB boosted its position in Royalty Pharma by 10.3% during the 4th quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company's stock valued at $310,308,000 after acquiring an additional 1,136,800 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Royalty Pharma by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 7,312,551 shares of the biopharmaceutical company's stock valued at $186,846,000 after purchasing an additional 46,765 shares in the last quarter. Norges Bank purchased a new stake in Royalty Pharma in the fourth quarter worth $124,498,000. Charles Schwab Investment Management Inc. raised its holdings in Royalty Pharma by 4.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company's stock worth $79,888,000 after purchasing an additional 130,025 shares in the last quarter. Finally, New South Capital Management Inc. lifted its position in Royalty Pharma by 19.9% during the fourth quarter. New South Capital Management Inc. now owns 2,957,125 shares of the biopharmaceutical company's stock valued at $75,436,000 after buying an additional 490,754 shares during the period. 54.35% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Royalty Pharma presently has an average rating of "Buy" and a consensus price target of $42.50.

Royalty Pharma Stock Up 0.2 %

NASDAQ:RPRX traded up $0.08 during trading hours on Friday, reaching $32.11. 886,580 shares of the company traded hands, compared to its average volume of 3,244,052. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $34.20. The stock has a market capitalization of $18.51 billion, a P/E ratio of 22.15, a P/E/G ratio of 2.31 and a beta of 0.50. The business's 50-day moving average price is $32.54 and its two-hundred day moving average price is $29.39. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 2.74%. The ex-dividend date is Friday, May 16th. Royalty Pharma's dividend payout ratio (DPR) is currently 60.69%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.